ACA And Medicaid Will Squeeze Margins Though Tech Will Aid

Key Takeaways

• Elevated costs in government-backed plans and greater reliance on value-based care could compress margins despite operational improvements and diversification strategies.
  
• Increasing regulatory changes, political uncertainty, and provider sophistication in technology may erode pricing power and add to earnings volatility.
  
• Margin and earnings growth are threatened by rising healthcare costs, regulatory uncertainty, slow Medicaid rate realignment, provider power, and integration risks from recent acquisitions.

Catalysts

Operates as a health benefits company in the United States.

• While Elevance Health benefits from the long-term aging population in the U.S. which is expected to drive ongoing demand and increase premium revenues, the company faces persistent pressures from accelerated cost trends in its ACA and Medicaid businesses. This dynamic is likely to weigh on near-term revenues and net margins, given lagging rate recovery from state partners and ongoing risk pool deterioration.
  
• Despite significant advancements in technology and digital health integration-such as AI-enabled tools and analytics designed to drive administrative efficiencies and cost reductions-Elevance Health must contend with increasing sophistication among providers in using these same technologies for more aggressive coding and dispute resolution. This may continue to challenge cost controls and erode operating margins.
  
• Although value-based care models are expanding within Elevance's portfolio (now comprising over one-third of benefit expense in downside risk arrangements), elevated utilization in high-cost categories like emergency room visits, behavioral health, and specialty pharmacy threaten to outweigh the benefits of these models, resulting in higher-than-anticipated benefit expense ratios and margin compression in the long term.
  
• While strategic diversification through Carelon subsidiaries and risk-based services is expected to boost long-term service revenue and margin resilience, ongoing industry reforms-such as potential expiration of enhanced ACA subsidies and new Medicaid work requirements-introduce uncertainty about future enrollment levels and risk pool composition, putting pressure on both future revenue growth and margin visibility.
  
• Even though the company is exercising disciplined pricing and investment in operational improvements, heavy exposure to government-backed business exposes Elevance Health to reimbursement risk, political uncertainty, and delays in rate alignment. These factors create potential for ongoing volatility in earnings, especially if policy shifts or future reforms suppress the share or profitability of private insurance.

Elevance Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Elevance Health compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Elevance Health's revenue will remain fairly flat over the next 3 years.
• The bearish analysts assume that profit margins will increase from 2.6% today to 3.2% in 3 years time.
• The bearish analysts expect earnings to reach $6.5 billion (and earnings per share of $32.0) by about May 2029, up from $5.2 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $7.3 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 12.3x on those 2029 earnings, down from 16.3x today. This future PE is lower than the current PE for the US Healthcare industry at 22.4x.
• The bearish analysts expect the number of shares outstanding to decline by 3.56% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.19%, as per the Simply Wall St company report.

Risks

• Persistent elevated medical cost trends in the ACA and Medicaid businesses, driven by higher acuity, risk pool deterioration, and increased utilization-especially in behavioral health and specialty pharmacy-could erode net margins and constrain earnings recovery for several years.
  
• Delays in Medicaid rate alignment due to lagging state responses and complex redetermination cycles create prolonged margin suppression, introducing significant uncertainty to the pace of margin improvement and potentially reducing revenue and profitability.
  
• Regulatory and policy uncertainties, such as the expiration of ACA enhanced subsidies, new Medicaid work requirements, and more frequent eligibility reviews, may further destabilize enrollment and risk pools, intensifying margin volatility and threatening top-line growth.
  
• Heightened provider bargaining power, aggressive coding practices-enabled by AI-and the misuse of dispute resolution processes are raising allowed amounts and compliance costs, which could compress operating margins and increase administrative expenses.
  
• Scale-up and integration risk from recent acquisitions, combined with a strategic emphasis on embedding value-based care arrangements with greater downside risk, may subject Elevance Health to execution missteps and financial volatility, impacting both net income and long-term earnings visibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Elevance Health is $331.0, which represents up to two standard deviations below the consensus price target of $388.95. This valuation is based on what can be assumed as the expectations of Elevance Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $474.0, and the most bearish reporting a price target of just $331.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $204.8 billion, earnings will come to $6.5 billion, and it would be trading on a PE ratio of 12.3x, assuming you use a discount rate of 7.2%.
• Given the current share price of $392.68, the analyst price target of $331.0 is 18.6% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.